Results 91 to 100 of about 1,579,650 (291)

Basis of PD1/PD-L1 Therapies [PDF]

open access: yesJournal of Clinical Medicine, 2019
It is obvious that tumor cells have developed a number of strategies to escape immune surveillance including an altered expression of various immune checkpoints, such as the programmed death-1 receptor (PD-1) and its ligands PD-L1 and PD-L2. The interaction between PD-1 and PD-L1 results in an activation of self-tolerance pathways in both immune cells ...
openaire   +2 more sources

Dual Role of Tamoxifen in Enhancing STING and CEACAM1 Expression to Prime a Favorable Tumor Microenvironment for Anti‐TIM3 Immunotherapy

open access: yesAdvanced Science, EarlyView.
Anti‐PD‐1/PD‐L1 blockade has revolutionized cancer immunotherapy, but is ineffective against endocrine‐treated (i.e., Tamoxifen), relapsed ER+ breast cancer (BC) patients. This study provides insight into the sub‐optimal response of ER+BCs to anti‐PD‐1/PD‐L1 blockade – highlighting the induction of STING and the CEACAM1/TIM3 axis after chronic ...
Marvin Angelo E Aberin   +20 more
wiley   +1 more source

Additional file 6 of Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease

open access: yes, 2020
Additional file 6: Figure S4. Immunofluorescent double staining of PD-L1 and CD20 in AITL: PD-L1 (Alexa Fluor-488, green), CD20 (Cy3, red). Nuclei counterstained with DAPI (blue channel).
Markus Tiemann (8545260)   +3 more
core   +1 more source

Aptamer‐Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer

open access: yesAdvanced Science, EarlyView.
Prostate cancer is immunologically ‘cold’, with scarce, dysfunctional type 1 conventional dendritic cells (cDC1s) that limit T cell priming. We introduce an aptamer‐targeted liposomedelivering FMS‐like tyrosine kinase 3 ligand (Flt3L) and chlorin e6 (Ce6). Ultrasound induces antigen release and cDC1s recruitment, creating an in situ cDC1 vaccine.
Jiayi Wang   +8 more
wiley   +1 more source

N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1

open access: yesMolecular Cancer
Background The PD-L1/PD-1 pathway is crucial for immune regulation and has become a target in cancer immunotherapy. However, in order to improve patient selection for immune checkpoint blockade (ICB) therapies, better selection criteria are needed.
Bar Kaufman   +13 more
doaj   +1 more source

Engineering Approaches to Modify Immunomodulatory Functions of Mesenchymal Stromal Cells (MSCs): Tissue Regeneration and Clinical Application

open access: yesAdvanced Science, EarlyView.
Mesenchymal stromal cells (MSCs) show promise for treating immune‐related disorders through immunomodulation and tissue regeneration. This review gives a brief overview of current clinical approval of MSC therapies. It also discussed how bioengineering, including genetic modification, biomaterial delivery, extracellular vesicles, and iPSC‐derived MSCs,
Sichen Yang   +6 more
wiley   +1 more source

Clinicopathological association of programmed death-ligand 1 (PD-L1) expression in uterine cervical carcinomas: A cross-sectional observational study

open access: yesIndian Journal of Pathology and Microbiology
Background: Programmed death ligand (PD-L1) binds to its receptor PD-1 on T-cells and inhibits the immune response of T-lymphocytes. Cancer cells evade immune surveillance by upregulating PD-L1 expression, leading to tumor progression.
Md Ashab Anwer   +5 more
doaj   +1 more source

Summary results for patients in the PD-L1-high model.

open access: yes, 2020
Summary results for patients in the PD-L1-high model.
Juan Wisnivesky (8374794)   +6 more
core   +1 more source

ROS Self‐Supply Nanoplatform Based on Fenton Catalyst for Chemodynamic and Immunotherapy: Reprogramming Cold Tumor Into Hot Tumor in Cancer Treatment

open access: yesAdvanced Science, EarlyView.
A multifunctional HA‐conjugated nanoplatform (HA‐PGMC) integrates CuO2, glucose oxidase, and mil‐100 to enable cascade catalytic ROS generation in tumor microenvironments. This self‐supplying ROS strategy induces immunogenic cell death, reprograms “cold” tumors into “hot” ones, and synergizes with PD‐L1 blockade, achieving potent chemodynamic ...
Man Lung Lee   +6 more
wiley   +1 more source

An Activity‐Reinforced P‐Modified Single‐Atom Cu Nanozyme Potentiates IDO Blockade‐Induced Tumor Radiotherapy

open access: yesAdvanced Science, EarlyView.
A phosphorus‐modified single‐atom copper nanozyme delivering the IDO1 inhibitor 1‐methyl‐tryptophan enhances breast cancer radioimmunotherapy by simultaneously relieving hypoxia and inducing immunogenic cell death through dual enzyme activities while blocking tryptophan metabolism to suppress regulatory T cell function.
Wei Zhao   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy